CN112641894B - A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction - Google Patents

A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction Download PDF

Info

Publication number
CN112641894B
CN112641894B CN202110069638.0A CN202110069638A CN112641894B CN 112641894 B CN112641894 B CN 112641894B CN 202110069638 A CN202110069638 A CN 202110069638A CN 112641894 B CN112641894 B CN 112641894B
Authority
CN
China
Prior art keywords
group
traditional chinese
chinese medicine
medicine composition
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110069638.0A
Other languages
Chinese (zh)
Other versions
CN112641894A (en
Inventor
张冰
林志健
王雨
郭鹏杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing University of Chinese Medicine
Original Assignee
Beijing University of Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing University of Chinese Medicine filed Critical Beijing University of Chinese Medicine
Publication of CN112641894A publication Critical patent/CN112641894A/en
Application granted granted Critical
Publication of CN112641894B publication Critical patent/CN112641894B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/90Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a traditional Chinese medicine composition for regulating lipid metabolism and improving gastrointestinal dysfunction. The Chinese medicinal composition can be applied to medicaments, health-care products and functional foods for preventing and treating lipid metabolism disorder and gastrointestinal dysfunction. The lipid metabolism disorder of the present invention includes hyperlipidemia, hypertriglyceridemia and/or low density lipidemia, and the gastrointestinal dysfunction includes gastrointestinal absorption disorder, intestinal motility disorder and/or constipation or diarrhea caused by intestinal flora. The medicines of the traditional Chinese medicine composition belong to medicine and food dual-purpose medicines, and no obvious toxic or side effect is found in acute toxicity tests.

Description

A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction
Technical Field
The invention relates to a new traditional Chinese medicine combination for regulating lipid metabolism and improving intestinal functions by compatibility of chicory root, tuckahoe and glabrous greenbrier rhizome, belonging to the technical field of traditional Chinese medicines.
Background
Hyperlipidemia is a metabolic disorder caused by one or more abnormal blood lipid levels, and the clinical routine examination indexes comprise total cholesterol, triglyceride, low density lipoprotein and high density lipoprotein. In recent years, with the improvement of living standard, the intake of high fat food is increasing, and bad living habits such as exercise and smoking are lacking, so that the incidence of hyperlipidemia is increasing. Hyperlipidemia acts as an independent risk factor for various cardiovascular diseases. The incidence of cardiovascular and cerebrovascular diseases and the mortality rate are also increased year by year. Recent epidemiological research results indicate that the incidence of hyperlipidemia is rising year by year and is becoming younger. The rate of dyslipidemia of adults in China is 40.4%, and more than two fifths of adults in China are seriously affected by hyperlipidemia diseases. The burden of hyperlipemia diseases is continuously increased, the risk of cardiovascular and fatty liver diseases such as cerebral apoplexy, myocardial infarction, coronary heart disease and the like is increased, and the life health and the life quality of people are seriously damaged.
Gastrointestinal dysfunction is also called gastrointestinal neurosis and is manifested by dyspepsia, constipation or diarrhea, and the pathogenesis of the gastrointestinal dysfunction is not known uniformly at present. Along with the improvement of living standard and working pressure, the incidence of gastrointestinal diseases related to gastrointestinal dysfunction is continuously increased, and emotions, diet and the like can induce or aggravate the disease condition, relate to people of all ages, and have serious influence on the living quality. And specific drugs are not available clinically for treating gastrointestinal dysfunction.
The chicory root, the tuckahoe and the glabrous greenbrier rhizome are all traditional Chinese medicinal materials with longer medicinal and edible histories, and have high safety. Chicory root and tuckahoe are the species recorded in the list of articles which are both food and medicine and published by the ministry of health, and glabrous greenbrier rhizome is listed in the list of articles which can be used for health food.
The chicory root has the effects of clearing liver, benefiting gallbladder, strengthening spleen, eliminating dampness, clearing heat and reducing swelling; the tuckahoe has the effects of promoting diuresis, eliminating dampness, strengthening spleen and calming heart; glabrous greenbrier rhizome, rhizoma Smilacis Glabrae is used for removing toxic substance and promoting diuresis. The subject combines the traditional medicine application and the modern pharmacological research, the chicory root, the tuckahoe and the glabrous greenbrier rhizome are combined and compatible, the traditional Chinese medicine composition is considered to be capable of regulating the lipid metabolism of the organism and improving the intestinal dysfunction, and the pharmacological action of the traditional Chinese medicine composition has the advantages of multiple ways and multiple targets. Further intensive research can develop the health care product, the medicine, the functional food and the like with the functions of reducing fat, losing weight, relaxing bowels, regulating intestinal functions and relevant functions.
Disclosure of Invention
The invention provides a new combination of traditional Chinese medicines, which is applied to medicines and health products for preventing and treating lipid metabolism disorder and improving diseases related to gastrointestinal dysfunction.
The traditional Chinese medicine of the invention comprises: 9-18 parts of chicory root, 10-15 parts of poria cocos and 15-60 parts of rhizoma smilacis glabrae.
Preferably, the traditional Chinese medicine composition of the invention comprises: 12-17 parts of chicory root, 10-12 parts of tuckahoe and 25-40 parts of glabrous greenbrier rhizome.
Further preferably, the traditional Chinese medicine composition of the invention comprises: 15 parts of chicory root, 10 parts of tuckahoe and 30 parts of glabrous greenbrier rhizome.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods with the effect of reducing blood fat.
The invention provides application of the traditional Chinese medicine composition in preparation of medicines, health-care products and functional foods with weight-losing efficacy.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for treating intestinal dysfunction and/or constipation.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for promoting intestinal peristalsis.
The invention provides application of the traditional Chinese medicine composition in preparing medicines, health-care products and functional foods for regulating intestinal flora.
The chicory root is the dry root of compositae plant Cichorium hirsutum Candidulosum Boiss.et Huet or Cichorium intybus L. Slightly bitter, salty and cool. It enters liver, gallbladder and stomach meridians. Clearing liver-fire and promoting bile flow; strengthening stomach and promoting digestion; induce diuresis to alleviate edema. Jaundice due to damp-heat pathogen; stomach ache and poor appetite; edema and oliguria.
The Poria cocos is dried sclerotium of Wolf of Poria cos (Schw.) Wolf, a fungus of Polyporaceae. Sweet, bland and mild in taste. It enters heart, lung, spleen and kidney meridians. Clearing damp and promoting diuresis; invigorating spleen; and (4) calming the heart. Edema and oliguria are predominant; phlegm-fluid retention with dizziness and palpitation; poor appetite due to spleen deficiency; diarrhea due to loose stool; uneasiness of the heart; palpitations and insomnia.
The glabrous greenbrier rhizome is a dried rhizome of Smilax glabra Roxb. Sweet, bland and mild in taste. It enters liver and stomach meridians. Detoxification; dehumidifying; and (6) passing through the links. The spasm of limbs caused by syphilis and mercury poisoning; muscle and bone pain; drenching turbid damp heat; leucorrhea; abscess and swelling; scrofula; scabies and tinea.
The research takes WR-1339-induced hyperlipidemia mouse model, loperamide hydrochloride-induced constipation mouse model and lincomycin hydrochloride-induced intestinal flora disorder mouse as experimental objects, and researches the influence of the traditional Chinese medicine composition on lipid metabolism level, intestinal peristalsis function and intestinal flora structure ratio. The clinical total effective rate reaches more than 85 percent, and the blood fat improving effect is better when the composition is matched with statin lipid-lowering drugs. No obvious adverse reaction occurs in all cases.
Drawings
FIG. 1 shows the stool morphology of the constipated mice in each group.
The following experimental examples and examples are intended to further illustrate the present invention.
Experimental example 1 Effect of Chinese medicinal composition on lipid metabolism level of hyperlipidemic mouse
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome.
2. Method of producing a composite material
Kunming mouse, male, weight 18-22 g. The body weights were randomly divided into a normal group, a model group, a positive drug fenofibrate group, a traditional Chinese medicine combination high dose group, and a traditional Chinese medicine combination low dose group. The normal group and the model group are injected with gastric distilled water, the other groups of animals are given with the corresponding drug for 7d, 1 time per day, 16 hours before the last administration, the normal group is injected with normal saline (10ml/kg) in the abdominal cavity, and the other groups are injected with 5% Trition WR-1339 in the abdominal cavity with the same volume to induce the hyperlipidaemia mouse model. 1h after the last administration, blood is taken from the eyeball, centrifuged at 3000 rpm, serum is separated, and the levels of Total Cholesterol (TC), Triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) in the serum are detected. The experimental results are as follows:
(1) the effect on serum blood lipid (TC, TG, HDL-C, LDL-C) levels in hyperlipidemic mice is shown in Table 1.
Table 1. blood lipid levels (mmol/L,
Figure BDA0002905317500000041
)
Figure BDA0002905317500000042
in comparison with the normal group,*P<0.05,**P<0.01; in comparison to the set of models,#P<0.05,##P<0.01。
the results show that the serum TC, TG and LDL-C levels of the model group mice are obviously increased (P <0.01) and the HDL-C level is obviously reduced (P <0.01) compared with the normal group. Compared with the model group, the serum TG and LDL-C levels of the fenofibrate group are obviously reduced (P <0.05), the serum TG level of the high-dose group is obviously reduced (P <0.05), and the serum LDL-C level of the low-dose group is obviously reduced (P < 0.01). The experiment result 1 shows that the high dosage of the traditional Chinese medicine composition can obviously reduce the serum TG level of the hyperlipidemic mouse, and the low dosage of the traditional Chinese medicine composition can obviously reduce the LDL-C level of the hyperlipidemic mouse. The high-dose traditional Chinese medicine composition has the function of assisting in reducing the blood fat and the triglyceride, and the low-dose traditional Chinese medicine composition has the function of assisting in reducing the blood fat and the low-density lipoprotein. The small compound prescription with different dosages has different degrees of treatment effect on the hyperlipoidemia.
(2) The results of the effects on the body weight of the hyperlipidemic mice are shown in Table 2.
Table 2. body weight levels (g,
Figure BDA0002905317500000043
)
group of Example number (n) Body weight
Normal group 10 28.62±0.94
Model set 10 28.43±0.98
Fenofibrate group 10 28.52±1.08
High-dose group of traditional Chinese medicine composition 10 28.10±1.21
Low-dose group of traditional Chinese medicine composition 10 28.83±1.11
The results show that no obvious difference is found in body weight among groups, and the animals in each group have good growth condition and good hair color spirit during the experiment.
Experimental example 2 Effect of Chinese medicinal composition on Constipation gastrointestinal function of mice
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome.
2. Method of producing a composite material
Half of Kunming mouse, 18-22 g. The weight of the composition is randomly divided into a normal group, a model group, a positive drug mosapride group, a traditional Chinese medicine combination high-dose group and a traditional Chinese medicine combination low-dose group, and each group contains 12 drugs. Except for normal groups, each group of animals is perfused with 0.4ml of loperamide hydrochloride capsules (10mg/kg) for 1 time per day for 3 days continuously, and a slow-transit constipation mouse model is shaped, so that the model success standard is determined by that mice have hypokinesia, curl, slow movement, obvious hardened and small excrement and water content obviously reduced by naked eyes. After 3d of modeling, the positive group of mice is intragastrically administered with Mosapride citrate (2.25mg/kg), and the observation group is intragastrically administered with a small compound; the mice in the normal group and the model group are infused with physiological saline with the same volume, and the infusion administration interval of the molding and the intervention is 30min and is continued for 6 days.
After 0.5h of the last administration, 0.25mL of 0.05% phenol red paste prepared from 1.5% cmc-Na was injected into each mouse, the eyeball was removed after 20min, blood serum was separated at 3000 rpm, and the levels of MTL (motilin), GAS (gastrin), and CCK (cholecystokinin) in the blood serum were measured. The stomach and small intestine of the mouse were removed, the stomach was cut open by stretching the greater curvature of the stomach, the contents were washed in a test tube with 4mL of distilled water, the residue was vortexed for 3min, centrifuged at 3500r/min for 10min, and the gastric emptying rate was measured. Simultaneously ligating the lower end of the pylorus and the cardia part, taking out the intestinal tract from the cardia to the tail end of the rectum, separating the pylorus, measuring the total length of the small intestine and the distance from the phenol red front to the pylorus, and calculating the intestinal propulsion rate.
(1) The effect of the combination of Chinese herbs on the gastric emptying rate of constipated mice is shown in Table 3.
Table 3. gastric emptying rate (%, n-12,
Figure BDA0002905317500000051
)
group of Gastric emptying rate (%)
Normal group 0.68±0.08
Model set 0.46±0.08*
Mosapride group 0.51±0.05
High-dose group of traditional Chinese medicine composition 0.55±0.05##
Traditional Chinese medicine composition low-dose group 0.53±0.06#
In comparison with the normal group,*P<0.01. in comparison to the set of models,#P<0.05,##P<0.01。
during the experiment, the gastric emptying rate was significantly reduced in the model group compared to the normal group (P < 0.01). After the last administration, the gastric emptying rate of the high-dose and low-dose groups is obviously improved (P <0.01 or P < 0.05).
(2) The effect of the combination of Chinese herbs on intestinal transit in constipated mice is shown in Table 4.
Table 4. intestinal propulsion rate (%,
Figure BDA0002905317500000061
)
group of Example number (n) Small intestine propulsion ratio (%)
Normal group 14 0.64±0.17
Model set 16 0.39±0.10*
Mosapride group 16 0.46±0.11
High-dose group of traditional Chinese medicine composition 16 0.54±0.19##
Low-dose group of traditional Chinese medicine composition 16 0.52±0.13##
In comparison with the normal group,*P<0.01. in comparison to the set of models,##P<0.01。
during the experiment, the small intestine propulsion rate was significantly reduced in the model group compared to the normal group (P < 0.01). After the last administration, the small intestine propulsion rate of the high-dose and low-dose groups is obviously improved (P < 0.01).
(3) The effect of the combination of Chinese herbs on the gastrointestinal hormone levels of constipated mice, the results are shown in Table 5.
Table 5. serum MTL, GAS, CCK levels (pg/ml, n-12,
Figure BDA0002905317500000062
)
group of MTL GAS CCK
Normal group 37.01±7.0 5.67±2.20 55.86±7.02
Model set 32.86±8.22 5.40±2.17 60.38±6.03
Mosapride group 35.34±8.26 6.72±3.05 52.68±6.17##
High-dose group of traditional Chinese medicine composition 34.36±5.04 6.48±3.05 50.92±8.02##
Low-dose group of traditional Chinese medicine composition 34.91±7.62 6.26±2.83 53.38±4.44##
In comparison to the set of models,##P<0.01。
during the experiment, compared with the normal group, the serum MTL and GAS levels of the model group are reduced, and the serum CCK level is increased. Compared with the model group, the serum MTL and GAS levels of the mosapride group are increased, and the serum CCK level is obviously reduced (P < 0.01); the serum MTL and GAS levels of the high and low dose groups of the traditional Chinese medicine composition tend to be increased, and the serum CCK level is obviously reduced (P < 0.01).
(4) The effect of the combination of Chinese herbs on the stool morphology of the constipated mice is shown in figure 1.
Compared with the feces of the normal group of mice, the feces of the model group have hardened texture, reduced volume and rough surface; compared with the feces of mice in a model group, the feces of each treatment group have softer texture, large volume and smooth surface.
Experimental example 3 influence of Chinese medicinal composition on intestinal flora-related indicators of mice with intestinal flora disturbance
1. Medicine and food additive
The traditional Chinese medicine composition water extract of chicory root, tuckahoe and glabrous greenbrier rhizome, brown liquid, and the dosage of each component is as follows: 15g of chicory root, 10g of poria cocos and 30g of rhizoma smilacis glabrae.
2. Method of producing a composite material
Kunming mouse, male, 18-22 g. The weight of the composition is randomly divided into a normal group, a natural recovery group, a positive drug bacillus subtilis dual viable bacteria particle group, a traditional Chinese medicine combination high dose group and a traditional Chinese medicine combination low dose group, and each group contains 8 active ingredients. Except for normal groups, animals of each group are perfused with lincomycin hydrochloride (300mg/ml)0.3ml 2 times a day for 3 days continuously, and mice models with intestinal flora disorder are shaped. And (4) performing intragastric administration of distilled water to animals in the normal group and the natural recovery group, and administering corresponding medicines to the other animals in each group for 7 days continuously. After 1h of the last administration, the eyes were removed and blood was collected, serum was separated at 3000 rpm, and Total Protein (TP), albumin, immunoglobulin G (IgG) levels in the serum were measured. Spleens were isolated, weighed, and spleen index calculated. Collecting small intestine mucus, and detecting secretory immunoglobulin A (sIgA) level. Collecting cecal contents, inoculating bacterial liquid diluted in a proper proportion into a plate paved with a corresponding culture medium, carrying out inverted culture in a biochemical incubator at 37 ℃ for 24-48h, identifying bacterial count, and calculating the colony formation number of each bacterial colony in bacterial liquid per milliliter.
(1) The results of the effects on spleen index in mice with disturbed intestinal flora are shown in Table 6.
Table 6. spleen index (%, n-8,
Figure BDA0002905317500000071
)
group of Spleen index
Normal group 0.37±0.002
Model set 0.37±0.001
Bacillus subtilis dual viable bacteria granule group 0.34±0.001
High-dose group of traditional Chinese medicine composition 0.36±0.001
Low-dose group of traditional Chinese medicine composition 0.38±0.001
The results showed no significant change in spleen index for each group of mice.
(2) The results of the effects on TP, albumin, IgG and sIgA levels of mice with disturbed intestinal flora are shown in Table 7.
Table 7. the TP, albumin, IgG, sIgA levels of each group of mice (n-8,
Figure BDA0002905317500000081
)
group of TP(μg/mL) Albumin (g/L) IgG(g/L) sIgA(μg/mL)
Normal group 75115.34±7394.71 28.64±3.30 0.0022±0.0002 9.58±0.82
Natural recovery group 60821.33±13397.48* 28.08±7.44 0.0022±0.0002 8.62±0.63*
Bacillus subtilis dual viable bacteria granule group 75319.74±12696.10# 27.57±4.41 0.0023±0.0001 8.76±0.66
High-dose group of traditional Chinese medicine composition 75071.53±16470.50 30.63±2.83 0.0023±0.0001 8.58±0.51
Low-dose group of traditional Chinese medicine composition 70808.15±19538.87 33.37±3.92 0.0024±0.0003 8.86±0.38
In comparison with the normal group,*P<0.05; in contrast to the natural recovery group,#P<0.05;P<0.1。
compared with the normal group, the serum TP and intestinal mucus sIgA levels of the mice in the natural recovery group are obviously reduced (P < 0.05). Compared with the natural recovery group, the serum TP and albumin levels of the traditional Chinese medicine combination high-dose group tend to be increased (P is 0.07).
(3) The results of the effects on the number of four main host bacteria in the intestinal tract of mice with disturbed intestinal flora are shown in Table 8.
TABLE 8 intestinal content of each group of mice four major host colony culture counts (CFU/mL, n 8, x + -s)
Group of Escherichia coli Enterococcus Bifidobacterium Lactobacillus strain
Normal group 5.92±0.19 6.03±0.18 8.38±0.17 7.98±0.15
Natural recovery group 8.16±0.19** 7.99±0.24** 8.24±0.12 7.96±0.08
Bacillus subtilis dual viable bacteria granule group 7.37±0.11## 7.45±0.11## 8.55±0.15## 7.86±0.27
High-dose group of traditional Chinese medicine composition 7.16±0.19## 7.20±0.25## 8.29±0.10 7.98±0.17
Low-dose group of traditional Chinese medicine composition 7.16±0.31## 7.36±0.34## 8.01±0.22## 7.79±0.12**
In comparison with the normal group,**P<0.01; in contrast to the natural recovery group,##P<0.01。
compared with the normal group, the serum TP and intestinal mucus sIgA levels of the mice in the natural recovery group are obviously reduced (P < 0.05). Compared with the natural recovery group, the serum TP and albumin levels of the traditional Chinese medicine combination high-dose group tend to be increased (P is 0.07). Compared with the normal group, the amount of Escherichia coli and enterococcus bacteria in the mice in the natural recovery group is obviously increased after the intestinal content is cultured (P < 0.01). Compared with a natural recovery group, the bacillus subtilis dual viable bacteria granular group mouse and the traditional Chinese medicine combined high-dose and low-dose group mouse have obviously reduced escherichia coli and enterococcus bacteria content after the intestinal content is cultured (P is less than 0.01); the amount of the bifidobacterium and lactobacillus in the low-dose group of the traditional Chinese medicine composition is obviously reduced.
Experimental example 4 optimization analysis of Chinese medicinal composition for hyperlipidemia mice
1. Medicine and food additive
The formula 1 is as follows: 15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome;
and (2) formula: 10g of chicory root, 15g of tuckahoe and 20g of glabrous greenbrier rhizome;
and (3) formula: 15g of chicory root, 20g of tuckahoe and 50g of glabrous greenbrier rhizome.
Each prescription is boiled and extracted by water, and is concentrated into brown liquid with the weight volume ratio of 1: 1.
2. Method of producing a composite material
Kunming mouse, male, weight 18-22 g. The weights of the patients are randomly divided into a normal group, a model group, a fenofibrate group, a formula 1 group, a formula 2 group and a formula 3 group. The normal group and the model group are injected with gastric distilled water, the other groups of animals are given with the corresponding drug for 7d, 1 time per day, 16 hours before the last administration, the normal group is injected with normal saline (10ml/kg) in the abdominal cavity, and the other groups are injected with 5% Trition WR-1339 in the abdominal cavity with the same volume to induce the hyperlipidaemia mouse model. 1h after the last administration, blood is taken from the eyeball, centrifuged at 3000 rpm, serum is separated, and the levels of Total Cholesterol (TC), Triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) in the serum are detected. The experimental results are as follows:
(1) the effects on serum blood lipid (TC, TG, HDL-C, LDL-C) levels in hyperlipidemic mice are shown in Table 9.
Table 9. blood lipid levels (mmol/L,
Figure BDA0002905317500000091
)
Figure BDA0002905317500000092
in comparison with the normal group,*P<0.05,**P<0.01; in comparison to the set of models,#P<0.05,##P<0.01。
the results show that the serum TC, TG and LDL-C levels of the model group mice are obviously increased (P <0.01) and the HDL-C level is obviously reduced (P <0.01) compared with the normal group. Compared with the model group, the serum TG and LDL-C levels of the fenofibrate group are obviously reduced (P < 0.05); the TG and LDL-C levels of the formula 1 group are obviously reduced (P is less than 0.05); and the effects of the compositions 2 and 3 are not obvious. The experimental results show that the group 1 can significantly reduce the serum TG and LDL-C levels of the mice with hyperlipidemia, and the group 1 (namely the composition of 15 parts by mass of chicory root, 10 parts by mass of tuckahoe and 30 parts by mass of glabrous greenbrier rhizome) is better in effect of reducing the blood fat.
Detailed Description
Example 1:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose into the above extract, and making into granule by conventional method.
Example 2:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, and making into oral liquid or functional beverage by conventional method.
Example 3:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, making into granule by conventional method, and making into capsule.
Example 4:
9-18g of chicory root, 10-15g of tuckahoe and 15-60g of glabrous greenbrier rhizome, wherein the extract is obtained by boiling and extracting for 2 times by 10 times of hot water for 90min each time, merging the boiling and extracting solutions and concentrating to obtain an extract.
Auxiliary materials: starch
Adding starch into the above extract, and making into capsule by conventional method.
Example 5:
9-18g of chicory root, 10-15g of tuckahoe, 15-60g of glabrous greenbrier rhizome, boiling and extracting for 2 times by 10 times of hot water, each time for 90min, merging boiling and extracting solutions, and concentrating to obtain an extract.
Auxiliary materials: dextrin
Adding dextrin into the above extract, and making into capsule by conventional method.
Example 6:
9-18g of chicory root, 10-15g of tuckahoe and 15-60g of glabrous greenbrier rhizome, wherein the extract is obtained by boiling and extracting for 2 times by 10 times of hot water for 90min each time, merging the boiling and extracting solutions and concentrating to obtain an extract.
Auxiliary materials: sorbitol
Adding sorbitol into the above extract, and making into capsule by conventional method.
Example 7:
15g of chicory root, 10g of tuckahoe and 30g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose into the above extract, and making into granule by conventional method.
Example 8:
12g of chicory root, 12g of tuckahoe and 35g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, and making into oral liquid or functional beverage by conventional method.
Example 9:
16g of chicory root, 11g of tuckahoe and 25g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: lactose
Adding lactose and CMC-Na into the above extract, making into granule by conventional method, and making into capsule.
Example 10:
14g of chicory root, 10g of tuckahoe and 40g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: starch
Adding starch into the above extract, and making into capsule by conventional method.
Example 11:
13g of chicory root, 15g of tuckahoe and 30g of glabrous greenbrier rhizome are boiled and extracted with 10 times of hot water for 2 times, each time is 90min, the boiling extracting solutions are combined and concentrated to obtain an extract.
Auxiliary materials: dextrin
Adding dextrin into the above extract, and making into capsule by conventional method.

Claims (7)

1. A traditional Chinese medicine composition for preventing and treating hyperlipidemia and intestinal dysfunction is characterized by being prepared from 15 parts by weight of chicory root, 10 parts by weight of poria cocos and 30 parts by weight of rhizoma smilacis glabrae.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition is added with pharmaceutically or physiologically acceptable auxiliary materials to prepare an application preparation.
3. Use of the Chinese medicinal composition according to claim 1 for the preparation of a medicament for the treatment of hyperlipidemia or intestinal dysfunction.
4. Use according to claim 3, wherein the intestinal dysfunction comprises constipation or intestinal flora disorders.
5. The use of claim 3, wherein the hyperlipidemia is caused by 5% Trition WR-1339 induced mice.
6. The use of claim 4, wherein the constipation is caused by induction of mice with loperamide hydrochloride.
7. The use according to claim 4, wherein the intestinal flora disturbance is caused by the induction of mice with lincomycin hydrochloride.
CN202110069638.0A 2020-01-19 2021-01-19 A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction Active CN112641894B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020100598792 2020-01-19
CN202010059879 2020-01-19

Publications (2)

Publication Number Publication Date
CN112641894A CN112641894A (en) 2021-04-13
CN112641894B true CN112641894B (en) 2022-06-17

Family

ID=75370565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110069638.0A Active CN112641894B (en) 2020-01-19 2021-01-19 A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction

Country Status (1)

Country Link
CN (1) CN112641894B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115300586B (en) * 2021-08-09 2023-10-10 北京中医药大学 Traditional Chinese medicine composition for resisting urate renal deposition and preparation method thereof
CN115715782B (en) * 2021-08-24 2023-12-26 北京中医药大学 Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463531A (en) * 2013-09-27 2013-12-25 张清峰 Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods
CN109748981A (en) * 2017-11-02 2019-05-14 中国科学院微生物研究所 A kind of alkali carries method and its application of pachymaran

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101791383A (en) * 2010-01-06 2010-08-04 崔晓廷 Compound chicory series product and effect of adjusting blood sugar, blood fat and blood uric acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463531A (en) * 2013-09-27 2013-12-25 张清峰 Use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods
CN109748981A (en) * 2017-11-02 2019-05-14 中国科学院微生物研究所 A kind of alkali carries method and its application of pachymaran

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
菊苣提取物对腹型肥胖大鼠肠道菌群的影响;孙博喻等;《中国中药杂志》;20140630;第39卷(第11期);第2081-2085页 *

Also Published As

Publication number Publication date
CN112641894A (en) 2021-04-13

Similar Documents

Publication Publication Date Title
CN102048933B (en) Chinese medicinal composition for treating infantile diarrhea and preparation method thereof
CN107496850B (en) It is a kind of adjust enteral microecological formulation formula and application
CN110787233B (en) Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof
CN112641894B (en) A new Chinese medicinal composition for regulating lipid metabolism and improving gastrointestinal dysfunction
CN102198262A (en) Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof
CN114470114B (en) Application of Mailuoshutong preparation in preparation of medicine for treating constipation
CN108434242A (en) A kind of pharmaceutical composition, preparation method and its usage for treating diabetes and its complication
CN108785594A (en) A kind of Chinese herbal ointment formula and preparation method for intervening phlegm-dampness constitution
CN112826889A (en) Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease
CN107412713A (en) Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
CN115252737A (en) Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease, preparation method and application
CN111375004B (en) Traditional Chinese medicine enema for treating non-alcoholic steatohepatitis and preparation method and application method thereof
CN114191515A (en) Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof
CN114158735A (en) Probiotic composition and application thereof
CN103720808B (en) A kind of composition and use thereof, preparation method with relieving constipation effect
CN103007145B (en) Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition
CN105796821A (en) Composition for removing food retention and relaxing bowels, preventing gastrointestinal cold and boosting immunity in children
CN104707126A (en) Medicament for treating streptococcus pneumonia infected pneumonia and preparation method thereof
CN110420297A (en) A kind of Chinese materia medica preparation for anti-trioxypurine
CN116370592B (en) Traditional Chinese medicine composition for treating non-alcoholic fatty liver fibrosis as well as preparation method and application thereof
CN108771658A (en) A kind of bowel relaxing oral liquid and preparation method
CN104324209B (en) One kind treats snorting Chinese medicine composition of pig and preparation method thereof
CN116832101B (en) Traditional Chinese medicine composition, preparation and application for treating spleen and stomach damp-heat syndrome of Hp related dyspepsia
CN103690771B (en) Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant